Organization
Ferrer Internacional
4 clinical trials
Clinical trial
A Multicenter, Open-label Extension Study to Investigate the Long-term Safety of FAB122 in Patients With Amyotrophic Lateral SclerosisStatus: Terminated, Estimated PCD: 2024-01-09
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 (Oral Formulation) to Slow the Disease Progression of Progressive Supranuclear Palsy (PSP) (PROSPER)Status: Not yet recruiting, Estimated PCD: 2026-11-01
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of FAB122 in Patients With Amyotrophic Lateral SclerosisStatus: Active (not recruiting), Estimated PCD: 2024-06-20